Merck Has Agreed To Acquire CN201, An Investigational Clinical-stage Bispecific Antibody For B-cell Associated Diseases, From A Privately Held Curon Biopharmaceutical For An Upfront Payment Of $700M In Cash And Up To $600M In Milestone Payments
Author: Benzinga Newsdesk | August 09, 2024 06:48am
CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively. Preliminary data suggest CN201 has activity in patients with relapsed or refractory B-cell hematologic malignancies and is well tolerated, with the potential to induce significant and sustained reductions in B-cell populations. Merck plans to evaluate CN201 as a treatment for B-cell malignancies as well as investigate its potential to provide a novel, scalable option for the treatment of autoimmune diseases.
Posted In: MRK